XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition - Additional Information (Details)
 3 Months Ended
Nov. 22, 2020
USD ($)
Program
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Deferred revenue, revenue recognized   $ 19,024,000 $ 12,782,000
Percentage of revenue expected to be recognized   52.00%  
Unsatisfied performance obligation   $ 25,654,000  
Maximum      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Contract with customers, payment terms   60 days  
Minimum      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Contract with customers, payment terms   30 days  
Agreement with Gates Ventures, LLC      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Contribution revenue related to agreement cover period start date   Jun. 23, 2020  
Contribution revenue related to agreement cover period end date   Jun. 22, 2023  
Contribution revenue recognition amount   $ 0 0
Contribution revenue recognition   1,000,000  
Deferred revenue   0  
Agreement with Gates Ventures, LLC | Maximum      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Contribution revenue recognition amount   3,000,000  
Agreement with Gates Ventures, LLC | First Anniversary      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Additional revenue entitled to receive   1,000,000  
Agreement with Gates Ventures, LLC | Second Anniversary      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Additional revenue entitled to receive   1,000,000  
Collaboration and License Agreement | BMS      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Upfront fee received $ 55,000,000    
Maximum milestone payments to be received $ 2,700,000,000    
Number of programs under agreement | Program 5    
Transaction price $ 55,000,000    
Deferred revenue, revenue recognized   2,383,000  
Deferred revenue   $ 51,629,000  
On Premise Software      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Revenue, practical expedient, financing component [true false]   true  
Drug Discovery      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Milestone payment yet to be achieved   $ 2,500,000 0
Revenue recognized with milestones   $ 2,213,000 $ 0
Oncology Product | Collaboration and License Agreement | BMS      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Maximum milestone payments to be received 585,000,000    
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones 360,000,000    
Milestone payments to be received upon achievement of certain specified commercial milestones 225,000,000    
Neurology and Immunology Product | Collaboration and License Agreement | BMS      
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]      
Maximum milestone payments to be received 482,000,000,000    
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones 257,000,000    
Milestone payments to be received upon achievement of certain specified commercial milestones $ 225,000,000